Volume 20, Issue 4 (January 2013)                   J Birjand Univ Med Sci 2013, 20(4): 327-337 | Back to browse issues page

XML Persian Abstract Print


1- Chronic Renal Failure Research Center, Ahwaz Jundishapur University of Medical Sciences, Ahvaz, Iran. , Beladimusavi@yahoo.com
2- Kidney Transplantation Complications Research Center, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
Abstract:   (23916 Views)
Cisplatin is a potent chemotherapy agent which is used to treat a broad spectrum of solid cancers. However, its clinical use is limited due to its nephrotoxicity with a decline in the glomerular filtration rate that occur in 15-30% of patients. Multiple mechanisms contribute to renal dysfunction following exposure to cisplatin include tubular epithelial cell toxicity, vasoconstriction in the renal microvasculature, and increase the expression of proinflammatory cytokines. The most important manifestations of cisplatin nephrotoxicity are non oliguric acute renal failure (ARF) which can be progressive, hypomagnesemia, fanconi-like syndrome, and anemia. An increasing risk of ARF is associated with higher doses of cisplatin, previous cisplatin chemotherapy, underlying kidney dysfunction, and the concomitant use of other nephrotoxic agents. The standard approach to prevent cisplatin-induced nephrotoxicity is the administration of lower doses of cisplatin in combination with the administration of full intravenous isotonic saline before and after cisplatin administration. Although a number of pharmacologic agents including sodium thiosulfate, N-acetylcysteine, theophylline and glycine have been evaluated for prevention of nephrotoxicity, none have proved to have an established role, thus, additional clinical studies will be required to confirm their probable effects.
Full-Text [PDF 167 kb]   (4844 Downloads)    
Type of Study: Review | Subject: Nephrology
Received: 2013/03/1 | Accepted: 2014/03/5 | ePublished: 2014/03/5

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.